Clinical data | |
---|---|
Trade names | Eperzan (Europe), Tanzeum (US) |
Other names | GSK-716155 |
AHFS/Drugs.com | tanzeum |
Routes of administration | Subcutaneous (SC) |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Protein binding | Probably none |
Metabolism | Most likely proteolysis |
Elimination half-life | 5 (4–7) days |
Identifiers | |
CAS Number | |
PubChem SID | |
DrugBank | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C3232H5032N864O979S41 |
Molar mass | 72971.34 g·mol−1 |
Albiglutide (trade names Eperzan in Europe and Tanzeum in the US) is a glucagon-like peptide-1 agonist (GLP-1 agonist) drug marketed by GlaxoSmithKline (GSK) for treatment of type 2 diabetes. As of 2017 it is unclear if it affects a person's risk of death.[2] In 2017 GSK announced Albiglutide's withdrawal from the worldwide market for economic reasons, and remaining stocks in the supply chain were effectively depleted by 2018.